ANAPTYSBIO, INC. Restricted Cash, Current
ANAPTYSBIO, INC. (ANAB) had Restricted Cash, Current of $60.00 thousand as of 2021-09-30, per its 10-Q filed 2021-11-04.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:RestrictedCashCurrent · last filed 2021-11-04
- 2021-09-30: Restricted Cash, Current $60.00K.
- 2021-06-30: Restricted Cash, Current $60.00K.
- 2021-03-31: Restricted Cash, Current $60.00K.
- 2020-12-31: Restricted Cash, Current $0.00.
| Period end | Restricted Cash, Current |
|---|---|
| 2021-09-30 | $60.00K 10-Q · filed 2021-11-04 |
| 2021-06-30 | $60.00K 10-Q · filed 2021-08-09 |
| 2021-03-31 | $60.00K 10-Q · filed 2021-05-04 |
| 2020-12-31 | $0.00 10-Q · filed 2021-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |